Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older
PHASE1
Brief Summary of Stage 1:
The purpose of Stage 1 (Phase I/IIa) was to asse...
Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years
PHASE1
VAV00039 is a first-in-human (FiH) study to assess the safety and immunogen...